(1S,8S,10R,13R)-10-(dimethoxymethyl)-6-[2-[4-(dimethylamino)phenyl]ethynyl]-2-oxa-9-azatetracyclo[6.5.1.01,5.09,13]tetradeca-4,6-dien-3-one

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯里西啶类
• 英文名称: (1S,8S,10R,13R)-10-(dimethoxymethyl)-6-[2-[4-(dimethylamino)phenyl]ethynyl]-2-oxa-9-azatetracyclo[6.5.1.01,5.09,13]tetradeca-4,6-dien-3-one
• 化学式: C₂₅H₂₈N₂O₄
• 分子量: 420.5
• InChiKey: FFCDMGQGQGZVFT-DYZUWXGSSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  31
• 可旋转键数：
  6
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.48
• 拓扑面积：
  51.2
• 氢给体数：
  0
• 氢受体数：
  6

文献信息

• Securinine and norsecurinine analogue compounds for the treatment of myeloid disorders
  申请人：CASE WESTERN RESERVE UNIVERSITY

  公开号：US10806723B2

  公开（公告）日：2020-10-20

  The present application relates to securinine or norsecurinine analogues that, when administered to immature myeloid cells, promote differentiation of these cells to mature cells that do not readily proliferate. Therefore, the agents are useful in the treatment of myeloid disorders including myeloproliferative disorders, acute myeloid leukemia, and autoimmune diseases. The agents may also be used as a myeloablative agent in conjunction with a bone marrow transplant or stem cell therapy.

  本申请涉及securinine或norsecurinine类似物，当对未成熟髓系细胞施用时，可促进这些细胞分化为不易增殖的成熟细胞。因此，这些制剂可用于治疗髓系疾病，包括骨髓增生性疾病、急性髓系白血病和自身免疫性疾病。这些制剂还可用作骨髓移植或干细胞疗法的髓鞘脱落剂。
• SECURININE AND NORSECURININE ANALOGUE COMPOUNDS FOR THE TREATMENT OF MYELOID DISORDERS
  申请人：CASE WESTERN RESERVE UNIVERSITY

  公开号：US20160263089A1

  公开（公告）日：2016-09-15

  The present application relates to securinine or norsecurinine analogues that, when administered to immature myeloid cells, promote differentiation of these cells to mature cells that do not readily proliferate. Therefore, the agents are useful in the treatment of myeloid disorders including myeloproliferative disorders, acute myeloid leukemia, and autoimmune diseases. The agents may also be used as a myeloablative agent in conjunction with a bone marrow transplant or stem cell therapy.
• [EN] SECURININE AND NORSECURININE ANALOGUE COMPOUNDS FOR THE TREATMENT OF MYELOID DISORDERS<br/>[FR] COMPOSÉS ANALOGUES DE SÉCURININE ET NORSÉCURININE POUR LE TRAITEMENT DE TROUBLES MYÉLOÏDES
  申请人：UNIV CASE WESTERN RESERVE

  公开号：WO2015051317A1

  公开（公告）日：2015-04-09

  The present application relates to securinine or norsecurinine analogues that, when administered to immature myeloid cells, promote differentiation of these cells to mature cells that do not readily proliferate. Therefore, the agents are useful in the treatment of myeloid disorders including myeloproliferative disorders, acute myeloid leukemia, and autoimmune diseases. The agents may also be used as a myeloablative agent in conjunction with a bone marrow transplant or stem cell therapy.